Skip to NavigationSkip to content

Roche's entrectinib shrinks lung tumours with two-year response duration

Published on 25/09/18 at 11:08am

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), showing the drug had long-term effects and reduced tumour size.

ROS1 gene fusions are present in around 1-2% of NSCLC patients, with NSCLC being the most common kind of lung cancer, accounting for 85% of all cases. Additionally, around 30-40% of ROS1-positive NSCLC have brain metastases at the time they receive their diagnosis.

In the studies, entrectinib demonstrated an objective response rate of 77.4%, shrinking tumours in more than three quarters of participants; furthermore, the drug also shrank tumours in 55% of patients with cancer of the central nervous system, and demonstrated a duration of response of 24.6 months.

“These results show the potential of precision medicines to deliver tailored and effective treatment options for people with non-small cell lung cancer, including those whose tumours have spread to the central nervous system,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We are also investigating entrectinib in NTRK fusion-positive tumours across several different cancer types, and look forward to presenting those results in the near future.”

Roche confirmed that this data will be presented at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, and will also be utilised in submissions to regulatory authorities around the world as it tries to secure approval for entrectinib.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches